Cancer Institute A national cancer institute
designated cancer center

Ronald Levy, MD

Publication Details

  • Dendritic cell vaccines for cancer immunotherapy ANNUAL REVIEW OF MEDICINE Timmerman, J. M., Levy, R. 1999; 50: 507-529

    Abstract:

    Human tumors express a number of protein antigens that can be recognized by T cells, thus providing potential targets for cancer immunotherapy. Dendritic cells (DCs) are rare leukocytes that are uniquely potent in their ability to present antigens to T cells, and this property has prompted their recent application to therapeutic cancer vaccines. Isolated DCs loaded with tumor antigen ex vivo and administered as a cellular vaccine have been found to induce protective and therapeutic anti-tumor immunity in experimental animals. In pilot clinical trials of DC vaccination for patients with non-Hodgkin's lymphoma and melanoma, induction of anti-tumor immune responses and tumor regressions have been observed. Additional trials of DC vaccination for a variety of human cancers are under way, and methods for targeting tumor antigens to DCs in vivo are also being explored. Exploitation of the antigen-presenting properties of DCs thus offers promise for the development of effective cancer immunotherapies.

    View details for Web of Science ID 000078831800032

    View details for PubMedID 10073291

Stanford Medicine Resources:

Footer Links: